Therapeutics

Owing to their target specificity, over 30% of drugs in development are biologics, most of which are antibodies and their derivatives. However, given their large size (~150 kDa), conventional antibodies pose certain issues such as immunogenicity, inefficient tissue penetration, and less than optimal biodistribution. These limitations led to the development of trimmed down versions of antibodies such as the antigen-binding fragments (Fab fragments), variable fragments (Fv fragments), and single chain variable fragments (scFv fragments). These antibody derived proteins and their stability are the constant areas of improvement and never-ending research.

The serendipitous discovery of small (~15 kDa), single chain antibodies from camelidae in the 1990s paved way for a new generation of biologics as therapeutics. With a major breakthrough in 2018 in Europe and in 2019 by the FDA, Caplacizumab a treatment for adults with acquired thrombotic thrombocytopenic purpura (aTTP) created history with proof of concept in humans.

At Mabgenex, we use a proprietary method to isolate specific antibodies that does not require conventional immunizations. Our method of antibody generation is efficient, effective, faster and cheaper. Using a combination of biology and Artificial Intelligence, the efficiency of clonal selection and optimization is significantly enhanced.